| Page 33 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis

Key Points
Higher mortality with reduced intensity regimens after haploidentical relative compared to matched unrelated donor transplantation

Higher grade III-IV acute graft versus host disease after haploidentical relative compared to matched unrelated donor transplantation

Yoga in Oncologic Care: An Evidence-Based Treatment to Improve Outcomes

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Increasingly, patients with cancer desire nonpharmacologic strategies for managing their symptoms. Yoga is a time-honored mind-body practice that has been shown to improve both physical and psychological well-being.

Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS

Author(s): 
Akshay Sharma, Ying Li, Sujuan Huang, Aimee C Talleur, Ali Suliman, Amr Qudeimat, Ashok Srinivasan, Ewelina Mamcarz, Renee Madden, Cheng Cheng, Stephen Gottschalk, Brandon M Triplett
Primary Author: 
Sharma A
Journal Title: 
Bone Marrow Transplantation
Original Publication Date: 
Mar 2021

Disease relapse remains a major cause of treatment failure in patients receiving allogeneic hematopoietic cell transplantation (alloHCT) for high-risk acute leukemias or

Bone Marrow Disease(s): 

Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia

Author(s): 
Fattizzo B, Ireland R, Dunlop A, Yallop D, Kassam S, Large J, Gandhi S, Muus P, Manogaran C, Sanchez K, Consonni D, Barcellini W, Mufti GJ, Marsh JCW, Kulasekararaj AG
Primary Author: 
Fattizzo B
Journal Title: 
Leukemia
Original Publication Date: 
Mar 2021

In this large single-centre study, we report high prevalence (25%) of, small (<10%) and very small (<1%),

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Author(s): 
Hillmen P, Szer J, Weitz I, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro C, Nishimori H, Tan L, Hamdani M, Deschatelets P, Francois C, Grossi F, Ajayi T, Risitano A, de la Tour RP
Primary Author: 
Hillman P
Journal Title: 
The New England Journal of Medicine
Original Publication Date: 
Mar 2021

Background: 

Bone Marrow Disease(s):